Sulfasalazine delayed-release 1000 mg – Ally for Managing Inflammatory Conditions.
FALAZINE 1000 DR Tablet: The composition of Sulfasalazine 1000 mg Delayed release is designed to bypass the stomach and release the active components directly in the intestines for targeted action. Once metabolised into sulfapyridine and 5-aminosalicylic acid (5-ASA), 5-ASA acts locally in the intestinal lining to reduce inflammation, making it highly effective for ulcerative colitis and Crohn’s disease. To minimise irritation to the upper digestive tract, it is suitable for long-term use in chronic conditions.
Recommended bY Specialists:
✅ Gastroenterologist –It is preferred to treat the disease associated with managing ulcerative colitis and other inflammatory bowel disease; delayed-release for fewer GI side effects
✅ Rheumatologist: It is preferred to treat the disease associated with treating rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis; DMARD benefits, GI protection from enteric coating
✅ General Physicians: It is preferred to treat the disease associated with a patient presenting with inflammatory bowel disease (IBD) symptoms (like chronic diarrhoea, rectal bleeding, abdominal pain) or early rheumatoid arthritis
Key benefits of Sulfasalazine Delayed Release 1000 mg Tablets – FALAZINE 1000 DR Tablet:
✅ Targeted Release Mechanism: The delayed-release formulation ensures the drug reaches the lower gastrointestinal tract, maximising its effectiveness in treating inflammatory bowel diseases.
✅ Dual Benefits: Combines anti-inflammatory and immunosuppressive actions, addressing both gut inflammation and joint pain.
✅ Optimised Tolerability: Reduces gastrointestinal side effects commonly associated with standard formulations, enhancing patient compliance.
INDICATIONS:
✅ Ulcerative Colitis
✅ Crohn’s Disease
✅ Rheumatoid Arthritis
✅ Ankylosing Spondylitis